Eric Angevin

12.9k total citations · 2 hit papers
140 papers, 6.5k citations indexed

About

Eric Angevin is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eric Angevin has authored 140 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 47 papers in Immunology and 39 papers in Molecular Biology. Recurrent topics in Eric Angevin's work include Cancer Immunotherapy and Biomarkers (40 papers), Immunotherapy and Immune Responses (34 papers) and Lung Cancer Treatments and Mutations (21 papers). Eric Angevin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (40 papers), Immunotherapy and Immune Responses (34 papers) and Lung Cancer Treatments and Mutations (21 papers). Eric Angevin collaborates with scholars based in France, United States and Netherlands. Eric Angevin's co-authors include Laurence Zitvogel, Thomas Tursz, Caroline Flament, Graça Raposo, Sebastián Amigorena, Bernard Escudier, Fabrice André, Joseph Wolfers, Anne Lozier and Florence Faure and has published in prestigious journals such as The Lancet, Circulation and Nature Medicine.

In The Last Decade

Eric Angevin

134 papers receiving 6.4k citations

Hit Papers

Tumor-derived exosomes are a source of shared tumor rejec... 2001 2026 2009 2017 2001 2002 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
    2001 1.3k citations Graça Raposo, Caroline Flament et al. profile →
  2. Malignant effusions and immunogenic tumour-derived exosomes
    2002 793 citations Fabrice André, Noël E.C. Schartz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Angevin France 38 3.8k 2.8k 1.7k 1.7k 814 140 6.5k
Leah Haworth United States 12 2.0k 0.5× 2.5k 0.9× 795 0.5× 3.2k 1.9× 1.2k 1.5× 21 6.1k
Veronica Huber Italy 31 5.0k 1.3× 3.1k 1.1× 3.0k 1.7× 1.6k 0.9× 434 0.5× 70 7.4k
Nikolai N. Khodarev United States 36 2.0k 0.5× 1.8k 0.7× 1.1k 0.6× 2.6k 1.5× 1.2k 1.4× 82 5.3k
Olivier Gires Germany 42 2.8k 0.7× 1.3k 0.5× 1.3k 0.8× 3.4k 2.0× 496 0.6× 109 6.2k
Gregory A. Daniels United States 28 2.4k 0.6× 1.5k 0.5× 1.5k 0.9× 3.3k 1.9× 1.2k 1.4× 116 6.0k
Gunnar Kvalheim Norway 43 1.7k 0.4× 1.8k 0.7× 890 0.5× 2.9k 1.7× 571 0.7× 173 5.5k
Thomas E. Darga United States 25 1.6k 0.4× 2.5k 0.9× 746 0.4× 3.1k 1.9× 1.2k 1.5× 34 5.4k
Patrizia Nanni Italy 48 2.8k 0.7× 2.6k 0.9× 813 0.5× 2.5k 1.5× 1.1k 1.4× 171 6.5k
Hardev Pandha United Kingdom 50 3.4k 0.9× 1.8k 0.6× 745 0.4× 3.6k 2.1× 777 1.0× 223 7.8k
Iain A. McNeish United Kingdom 41 2.9k 0.8× 1.6k 0.6× 940 0.5× 2.9k 1.7× 492 0.6× 199 6.9k

Countries citing papers authored by Eric Angevin

Since Specialization
Citations

This map shows the geographic impact of Eric Angevin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Angevin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Angevin more than expected).

Fields of papers citing papers by Eric Angevin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Angevin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Angevin. The network helps show where Eric Angevin may publish in the future.

Co-authorship network of co-authors of Eric Angevin

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Angevin. A scholar is included among the top collaborators of Eric Angevin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Angevin. Eric Angevin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations
2.
Lefebvre, Anne‐Marie, Julien Adam, Céline Nicolazzi, et al.. (2023). The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 184. 107356–107356. 9 indexed citations
3.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations
4.
Camidge, D. Ross, Daniel Morgensztern, Rebecca S. Heist, et al.. (2021). Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma. Clinical Cancer Research. 27(21). 5781–5792. 60 indexed citations
5.
Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations
6.
Strickler, John H., Colin D. Weekes, John Nemunaitis, et al.. (2018). First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 36(33). 3298–3306. 104 indexed citations
7.
Verlingue, Loïc, Antoine Hollebecque, Ludovic Lacroix, et al.. (2018). Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Annals of Oncology. 29. viii667–viii667. 1 indexed citations
8.
9.
Kossaï, Myriam, Boris Duchemann, C. Boutros, et al.. (2015). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 89(3). 306–310. 8 indexed citations
10.
Deutsch, Éric, C. Le Péchoux, Laurence Faivre, et al.. (2015). Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Annals of Oncology. 26(6). 1223–1229. 42 indexed citations
11.
Escudier, Bernard, Viktor Grünwald, Alain Ravaud, et al.. (2014). Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research. 20(11). 3012–3022. 49 indexed citations
12.
Bièche, Ivan, Sophie Vacher, Sophie Richon, et al.. (2014). Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC Cancer. 14(1). 178–178. 20 indexed citations
13.
Angevin, Eric, José A. López-Martín, Chia‐Chi Lin, et al.. (2013). Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 19(5). 1257–1268. 103 indexed citations
14.
André, Fabrice, Nathalie Chaput, Noël E.C. Schartz, et al.. (2004). Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells. The Journal of Immunology. 172(4). 2126–2136. 418 indexed citations
15.
Chaput, Nathalie, Noël E.C. Schartz, Fabrice André, et al.. (2004). Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection. The Journal of Immunology. 172(4). 2137–2146. 224 indexed citations
16.
Terme, Magali, Elena Tomasello, Koji Maruyama, et al.. (2004). IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules. The Journal of Immunology. 172(10). 5957–5966. 56 indexed citations
17.
Chaput, Nathalie, Fabrice André, Noël E.C. Schartz, et al.. (2003). Exosomes et immunothérapie antitumorale. Bulletin du Cancer. 90(8). 695–698. 6 indexed citations
18.
Borg, Christophe, Julien Taı̈eb, Magali Terme, et al.. (2003). Immunothérapie fondée sur les cellules natural killer : implication des cellules dendritiques. Bulletin du Cancer. 90(8). 699–705. 1 indexed citations
19.
Fernandez, Nadine, et al.. (2002). Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.. PubMed. 13(1). 17–27. 58 indexed citations
20.
Motta, Iris, Fabrice André, Apiradee Lim, et al.. (2001). Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells. The Journal of Immunology. 167(3). 1795–1802. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leah Haworth Breakdown of academic impact, for papers by Veronica Huber Breakdown of academic impact, for papers by Nikolai N. Khodarev Breakdown of academic impact, for papers by Olivier Gires Breakdown of academic impact, for papers by Gregory A. Daniels Breakdown of academic impact, for papers by Gunnar Kvalheim Breakdown of academic impact, for papers by Thomas E. Darga Breakdown of academic impact, for papers by Patrizia Nanni Breakdown of academic impact, for papers by Hardev Pandha Breakdown of academic impact, for papers by Iain A. McNeish
Rankless by CCL
2026